The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 63 results
Sort by date: Descending
Encores: Not included
Sleep-wake disorders
ESRS 2026 PRESENTATION
REVITALYZ: A Phase 3, Double-Blind, Placebo-Controlled, Randomised Withdrawal Trial of Extended-Release Sodium Oxybate for Idiopathic Hypersomnia
AUTHOR(S)

Richard K. Bogan, MD, FCCP, FAASM1,2; John Harsh, PhD3; Sally Ibrahim, MD4,5; John C. Carter, MD5,6; Anne Marie Morse, DO7; Bruce C. Corser, MD8; Thomas Stern, MD9; Emmanuel Mignot, MD, PhD10; Yves Dauvilliers, MD, PhD11; Jacqueline Brooks, MBBCh, MRCPsych12; Brian Abaluck, MD12; Gretchen S. Richards, MS12

View presentation
Sleep-wake disorders
Sleep-wake disorders
ESRS 2026 POSTER
REVITALYZ: A Phase 3, Double-Blind, Placebo-Controlled, Randomised Withdrawal Trial of Extended-Release Sodium Oxybate for Idiopathic Hypersomnia
AUTHOR(S)

Richard K. Bogan, MD, FCCP, FAASM1,2; John Harsh, PhD3; Sally Ibrahim, MD4,5; John C. Carter, MD5,6; Anne Marie Morse, DO7; Bruce C. Corser, MD8; Thomas Stern, MD9; Emmanuel Mignot, MD, PhD10; Yves Dauvilliers, MD, PhD11; Jacqueline Brooks, MBBCh, MRCPsych12; Brian Abaluck, MD12; Gretchen S. Richards, MS12

View poster
Sleep-wake disorders
Sleep-wake disorders
ESRS 2026 PRESENTATION
Phase 2 and Long-Term Extension Results from Treatment With the Orexin 2 Receptor Agonist Alixorexton Demonstrated Clinically Meaningful Improvements in Symptoms of Narcolepsy Type 1 and 2
AUTHOR(S)

Giuseppe Plazzi1,2

View presentation
Sleep-wake disorders
Sleep-wake disorders
ESRS 2026 POSTER
Long-Term Safety, Tolerability, and Durability of Alixorexton: Interim Results From a Phase 2/3 Extension Study in Narcolepsy
AUTHOR(S)

Yves Dauvilliers,1,2 Emmanuel Mignot,3 Richard K. Bogan,4 Brendon J. Yee,5 Rafael Del Rio Villegas,6,7 Gert J. Lammers,8,9 Chad Ruoff,10 David T. Plante,11 Feng Miao,12 Derek Matthies,12 Sarah A. Chau,12 Michael J. Doane,12 Craig Hopkinson,12 Bhaskar Rege,12 Julie Himes,12 and Giuseppe Plazzi13,14

View poster
Sleep-wake disorders
Sleep-wake disorders
ESRS 2026 POSTER
Participant-Reported Cognitive Functioning and Fatigue in Participants with Narcolepsy Type 2 Treated With Alixorexton, an Orexin 2 Receptor Agonist, in the Vibrance-2 Study
AUTHOR(S)

Giuseppe Plazzi,1,2 Emmanuel Mignot,3 Rafael del Río Villegas,4,5 Bruce Corser,6 Brendon J. Yee,7 Diego García-Borreguero,8 Chad Ruoff,9 David T. Plante,10 Hailu Chen,11 Craig Hopkinson,11 Bhaskar Rege,11 Julie Himes,11 Michael J. Doane,11 and Richard K. Bogan12

View poster
Sleep-wake disorders
Sleep-wake disorders
CHEST 2026 POSTER
Improved Sleep Latency Throughout the Day With Once-Nightly Sodium Oxybate in People With Narcolepsy: Post Hoc Analysis of the Phase 3 REST-ON Trial
AUTHOR(S)

Michael J. Thorpy, MD1; Emmanuel Mignot, MD, PhD2; Bruce C. Corser, MD3; Laura B. Herpel, MD4,5; Luis E. Ortiz, MD6; Jacqueline Brooks, MBBCh, MRCPsych7; Yves Dauvilliers, MD, PhD8

View poster
Sleep-wake disorders